title: Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
abstract: The aim of the present prospective study was to assess the diagnostic benefit of UroVysion (Vysis-Abbott Laboratories, Downers Grove, IL) in the follow-up of patients with a history of high-grade non-muscle-invasive urothelial carcinoma of the bladder (NMIBC). An unselected cohort of 25 patients with a history of high-grade NMIBC was prospectively followed up by office-based cystoscopy, cytology, and UroVysion in 210 events. The sensitivity and specificity for standard combined cystoscopy and cytology were 78% and 83%, respectively. UroVysion yielded a considerably higher detection rate with 94% and 93%, respectively. In 89% of the follow-up events of patients with a history of previous carcinoma in situ (CIS) and negative cystoscopy but a positive UroVysion finding, CIS recurrence was noticed within 5 months. UroVysion is a worthwhile approach in patients with previous CIS, a high risk for the development of CIS, or previous unequivocal cytology suggestive of CIS, especially during or shortly after instillation therapy.
authors.affiliation: Dept of Urology, University Regensburg, Caritas-Hospital St. Josef, Landshuter Straße 65, 93053 Regensburg, Germany.
authors.forename: Hans-Martin
authors.initials: HM
authors.lastname: Fritsche
authors.forename: Maximilian
authors.initials: M
authors.lastname: Burger
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Dietmaier
authors.forename: Stefan
authors.initials: S
authors.lastname: Denzinger
authors.forename: Ekkehard
authors.initials: E
authors.lastname: Bach
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Otto
authors.forename: Matthias
authors.initials: M
authors.lastname: Doblinger
authors.forename: Stephan
authors.initials: S
authors.lastname: Schwarz
authors.forename: Hannes
authors.initials: H
authors.lastname: Buchner
authors.forename: Arndt
authors.initials: A
authors.lastname: Hartmann
mesh_terms: D002278:Carcinoma in Situ / Q000473:pathology*; D002295:Carcinoma, Transitional Cell / Q000473:pathology*; D003558:Cystoscopy; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D016015:Logistic Models; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology*; D019459:Urothelium / Q000473:pathology
chemical_list: D011933:Reagent Kits, Diagnostic